Kramer Rubin (colorclam86)

Since lips have a significant role in facial aesthetic perception, lip augmentation is an increasingly popular aesthetic procedure. To evaluate aesthetic improvement and facial dynamics with hyaluronic acid (HA) fillers in the lips and perioral region at 8 weeks after the last treatment compared to pre-treatment. In this open-label study, all subjects received HARK in the lips, and an additional group also received HARR and/or HARD in nasolabial folds (NLFs) and marionette lines (MLs). Assessments included aesthetic improvement, naturalness of facial expressions, perception of age, and lip texture. Nineteen subjects received HARK only; 40 received HARK and HARR and/or HARD. The primary objective was met. All subjects experienced aesthetic improvement in lip fullness at week 8. The investigators also reported aesthetic improvement in all subjects. For the majority of subjects, aesthetic improvement was associated with maintenance of natural and youthful facial expressions, and improved lip texture. Most treatment-emergent adverse events were mild; none were serious. HARK is a well-tolerated and effective treatment for enhancing lip fullness, maintaining naturalness and youthfulness of facial expressions, and smoothing lip texture, whether used alone or in combination with HARR/ HARD in the NLFs and/or MLs. J Drugs Dermatol. 20(4) 402-408. doi10.36849/JDD.2021.5525. HARK is a well-tolerated and effective treatment for enhancing lip fullness, maintaining naturalness and youthfulness of facial expressions, and smoothing lip texture, whether used alone or in combination with HARR/ HARD in the NLFs and/or MLs. J Drugs Dermatol. 20(4) 402-408. doi10.36849/JDD.2021.5525. Biologic treatments have taken the forefront in treating moderate-to-severe psoriasis. Although numerous randomized, controlled trials have demonstrated the efficacy of these agents, there is limited data suggesting that clinical trial outcomes are reproducible in real-world patients. Obtain real-world evidence for the use of biologics that target different segments of the immune system in patients with moderate-to-severe psoriasis. A retrospective chart review was conducted for 100 patients who initiated biologic therapy and had a follow-up visit within a 4- to 12-month period. Efficacy assessments included body surface area (BSA), Physician’s Global Assessment (PGA) scores, composite BSA×PGA scores, and the National Psoriasis Foundation (NPF) Treat to Target (TTT) goal of ≤1% BSA. Biologic treatment led to notable reductions in BSA, PGA, and BSA×PGA relative to baseline, with the majority (67.0%) of the population achieving NPF TTT goals at follow-up. Disease improvements were observed in all patients, regardless of baseline body weight, prior experience with biologics, or the specific immune target of the prescribed biologic. Long-term biologic therapy demonstrated effectiveness in treating patients with moderate-to-severe psoriasis. J Drugs Dermatol. 20(4)442-449. doi10.36849/JDD.2021.5823Visit the Psoriasis Resource Center for more. Long-term biologic therapy demonstrated effectiveness in treating patients with moderate-to-severe psoriasis. J Drugs Dermatol. 20(4)442-449. doi10.36849/JDD.2021.5823Visit the Psoriasis Resource Center for more. This study was designed to evaluate the ameliorative effect of almond ( ) leaf (ALE) and stem bark (ABE) extracts on the enzyme activities and oxidative stress markers in the brain and liver tissues of cyclosporine-A (CsA) stressed male albino rats. Eighty-eight adult male rats weighing between 200 and 220g were randomly distributed to into 11 groups (n=8) and different doses (100 and 200mg/kg bwt.) of ALE and ABE were administered through oral gavages to the normal rats and 50mg/kg/bwt/day CsA-stressed, while normal control rats was given a saline solut